Current and prospective pharmacotherapies for the treatment of pleural mesothelioma

References

• Hispan P, Pascual JC, Gonzalez I, et al. Cutaneous metastases from malignant mesothelioma of the tunica vaginalis testis. Am J Dermatopathol. 2016 Mar;38(3):222–225.
   Google Scholar
• Segura-Gonzalez M, Urias-Rocha J, Castelan-Pedraza J. Malignant mesothelioma of the tunica vaginalis: a rare neoplasm–case report and literature review. Clin Genitourin Cancer. 2015 Dec;13(6):e401–5.
   Google Scholar
• Ismail-Khan R, Robinson LA, Williams CC Jr., et al. Malignant pleural mesothelioma: a comprehensive review. Cancer Control: J Moffitt Cancer Center. 2006 Oct;13(4):255–263.
   Google Scholar
• Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer. 1999 Feb;79(3–4):666–672.
   Google Scholar
• Neumann V, Loseke S, Nowak D, et al. Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health. Dtsch Arztebl Int. 2013 May;110(18):319–326.
   Google Scholar
• Roe OD, Stella GM. Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respiratory Review: Official Journal Eur Respir Soc. 2015 Mar;24(135):115–131.
   Google Scholar
• Mutti L. Malignant pleural mesothelioma: new ideas needed. Lung Cancer Manag. 2015 Oct 01;4(5):201–203.
   Google Scholar
• Guazzelli A, Hussain M, Krstic-Demonacos M, et al. Tremelimumab for the treatment of malignant mesothelioma. Expert Opin Biol Ther. 2015;15(12):1819–1829.
   Google Scholar
• Belli C, Fennell D, Giovannini M, et al. Malignant pleural mesothelioma: current treatments and emerging drugs. Expert Opin Emerg Drugs. 2009 Sep;14(3):423–437.
   Google Scholar
• Sugarbaker DJ, Wolf AS. Surgery for malignant pleural mesothelioma. Expert Rev Respir Med. 2010 Jun;4(3):363–372.
   Google Scholar
• Porpodis K, Zarogoulidis P, Boutsikou E, et al. Malignant pleural mesothelioma: current and future perspectives. J Thorac Dis. 2013 Sep;5(Suppl 4):S397–406.
   Google Scholar
• Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thoracic Oncology: off Pub Int Assoc Study Lung Cancer. 2007 Oct;2(10):957–965.
   Google Scholar
• Papaspyros S, Papaspyros S. Surgical management of malignant pleural mesothelioma: impact of surgery on survival and quality of life—relation to chemotherapy, radiotherapy, and alternative therapies. ISRN Surg. 2014 Feb 03:817203. Available from: https://www.hindawi.com/journals/isrn/2014/817203/.
   Google Scholar
• Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013 Feb 20;105(4):256–265.
   Google Scholar
• Remon J, Reguart N, Corral J, et al. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies. Cancer Treat Rev. 2015 Jan;41(1):27–34.
   Google Scholar
• Pinton G, Manente AG, Tavian D, et al. Therapies currently in Phase II trials for malignant pleural mesothelioma. Expert Opin Investig Drugs. 2013 Oct;22(10):1255–1263.
   Google Scholar
• Bertino P, Porta C, Barbone D, et al. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax. 2007 Aug;62(8):690–695.
   Google Scholar
• Wong RM, Ianculescu I, Sharma S, et al. Immunotherapy for malignant pleural mesothelioma. Current status and future prospects. Am J Respir Cell Mol Biol. 2014 May;50(5):870–875.
   Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2003 Jul 15;21(14):2636–2644.
   Google Scholar
• Leigh RA, Webster I. Lymphocytic infiltration of pleural mesothelioma and its significance for survival. S Afr Med J. 1982 Jun 26;61(26):1007–1009.
   Google Scholar
• Grégoire M. What’s the place of immunotherapy in malignant mesothelioma treatments? Cell Adh Migr. 2010 Jan–Mar;4(1):153–161.
   Google Scholar
• Lew F, Tsang P, Holland JF, et al. High frequency of immune dysfunctions in asbestos workers and in patients with malignant mesothelioma. J Clin Immunol. 1986 May;6(3):225–233.
   Google Scholar
• DeLong P, Carroll RG, Henry AC, et al. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther. 2005 Mar;4(3):342–346.
   Google Scholar
• Hegmans JP, Hemmes A, Aerts JG, et al. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am J Respir Crit Care Med. 2005 May 15;171(10):1168–1177.
   Google Scholar
• Astoul P, Picat-Joossen D, Viallat JR, et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer. 1998 Nov 15;83(10):2099–2104.
   Google Scholar
• Haas AR, Sterman DH. Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies. Clin Chest Med. 2013 Jan 17;34(1):99–111.
   Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252–264.
   Google Scholar
• Bakker E, Qattan M, Mutti L, et al. The role of microenvironment and immunity in drug response in leukemia. Biochim Biophys Acta. 2016 Mar;1863(3):414–426.
   Google Scholar
• Guazzelli A, Bakker E, Krstic-Demonacos M, et al. Anti-CTLA-4 therapy for malignant mesothelioma. Immunotherapy. 2017 Mar;9(3):273–280.
   Google Scholar
• Marcq E, Pauwels P, Van Meerbeeck JP, et al. Targeting immune checkpoints: new opportunity for mesothelioma treatment? Cancer Treat Rev. 2015 Dec;41(10):914–924.
   Google Scholar
• AstraZeneca. AstraZeneca reports top-line result of tremelimumab monotherapy trial in mesothelioma. 2016. Available from: https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-reports-top-line-result-of-tremelimumab-monotherapy-trial-in-mesothelioma-29022016.html
   Google Scholar
• Kindler HL, Scherpereel A, Calabrò L, et al. Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): results from the global, double-blind, placebo-controlled DETERMINE study. 2016 ASCO Annual Meeting; 2016; Chicago, IL.
   Google Scholar
• Alley EW, Molife LR, Santoro A, et al. Abstract CT103: clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: preliminary results from KEYNOTE-028. Cancer Res. 2015;75(15 Supplement):CT103–CT03.
   Google Scholar
• Hamanishi J, Mandai M, Matsumura N, et al. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol. 2016;21(3):462–473.
   Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. New England J Med. 2013;369(2):122–133.
   Google Scholar
• Doyle C. Combination immunotherapy superior to monotherapy in patients with melanoma. American Health Drug Benefits. 2015;8(Spec Issue):41–41.
   Google Scholar
• Krug LM, Dao T, Brown AB, et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immun. 2010 Oct;59(10):1467–1479.
   Google Scholar
• Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clinical Cancer Res: J Am Assoc Cancer Res. 2007 Sep 01;13(17):5076–5081.
   Google Scholar
• Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007 May;117(5):1195–1203.
   Google Scholar
• Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med. 2010 Jun 15;181(12):1383–1390.
   Google Scholar
• Van Der Most RG, Robinson BWS, Nelson DJ. Gene therapy for malignant mesothelioma: beyond the infant years [online]. Cancer Gene Ther. 2006 Jan 27;13(10):897–904.
   Google Scholar
• Smythe WR, Mohuiddin I, Ozveran M, et al. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J Thorac Cardiovasc Surg. 2002 Jun;123(6):1191–1198.
   Google Scholar
• Elshami AA, Kucharczuk JC, Zhang HB, et al. Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther. 1996 Jan 20;7(2):141–148.
   Google Scholar
• Sterman DH, Recio A, Vachani A, et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res. 2005 Oct 15;11(20):7444–7453.
   Google Scholar
• Jackaman C, Nelson DJ. Cytokine-armed vaccinia virus infects the mesothelioma tumor microenvironment to overcome immune tolerance and mediate tumor resolution [print]. Cancer Gene Ther. 2010 Jun;17(6):429–440.
   Google Scholar
• Zarogoulidis P, Darwiche K, Sakkas A, et al. Suicide gene therapy for cancer – current strategies. J Genet Syndr Gene Ther. 2013;4:16849.
   Google Scholar
• Qian C, Liu XY, Prieto J. Therapy of cancer by cytokines mediated by gene therapy approach. Cell Res. 2006 Feb;16(2):182–188.
   Google Scholar
• Sterman DH, Kanther M. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses (vol 13, pg 4456, 2007). Clin Cancer Res. 2007 Sep 1;13(17):5226–5326.
   Google Scholar
• Hoyos V, Savoldo B, Dotti G. Genetic modification of human T lymphocytes for the treatment of hematologic malignancies. Haematol-Hematol J. 2012 Nov;97(11):1622–1631.
   Google Scholar
• Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. P Natl Acad Sci USA. 2009 Mar 3;106(9):3360–3365.
   Google Scholar
• Schuberth PC, Hagedorn C, Jensen SM, et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J Transl Med. 2013 Aug 12;11:187.
   Google Scholar
• Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006 Sep;6(9):714–727.
   Google Scholar
• Hartmann JT, Haap M, Kopp HG, et al. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009 Jun;10(5):470–481.
   Google Scholar
• Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005 Dec;315(3):971–979.
   Google Scholar
• Pache JC, Janssen YM, Walsh ES, et al. Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers. Am J Pathol. 1998 Feb;152(2):333–340.
   Google Scholar
• Suzuki Y, Murakami H, Kawaguchi K, et al. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep. 2009 Mar–Apr;2(2):181–188.
   Google Scholar
• Janne PA, Taffaro ML, Salgia R, et al. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002 Sep 15;62(18):5242–5247.
   Google Scholar
• Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology-Basel. 2009;77(6):400–410.
   Google Scholar
• Mezzapelle R, Miglio U, Rena O, et al. Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma. Br J Cancer. 2013 Apr 30;108(8):1743–1749.
   Google Scholar
• Govindan R, Kratzke RA, Herndon JE 2nd, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clinical Cancer Res: J Am Assoc Cancer Res. 2005 Mar 15;11(6):2300–2304.
   Google Scholar
• Garland LL, Rankin C, Gandara DR, et al. Phase II Study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group study. J Clin Oncol. 2007 Jun 10;25(17):2406–2413.
   Google Scholar
• Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008 Aug 15;113(4):808–814.
   Google Scholar
• Destro A, Ceresoli GL, Falleni M, et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer. 2006 Feb;51(2):207–215.
   Google Scholar
• Cortese JF, Gowda AL, Wali A, et al. Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer. 2006 Jan 15;118(2):521–522.
   Google Scholar
• Kurai J, Chikumi H, Hashimoto K, et al. Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma. Int J Oncol. 2012 Nov;41(5):1610–1618.
   Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 04;144(5):646–674.
   Google Scholar
• Hoeben A, Landuyt B, Highley MS, et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004 Dec;56(4):549–580.
   Google Scholar
• Aoe K, Hiraki A, Tanaka T, et al. Expression of vascular endothelial growth factor in malignant mesothelioma. Anticancer Res. 2006 Nov-Dec;26(6C):4833–4836.
   Google Scholar
• Demirag F, Unsal E, Yilmaz A, et al. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest. 2005 Nov;128(5):3382–3387.
   Google Scholar
• Fujimoto N, Gemba K, Kishimoto T. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thoracic Oncology: off Pub Int Assoc Study Lung Cancer. 2011 May;6(5):971–972.
   Google Scholar
• Cohen MH, Gootenberg J, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin (R)) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007;12(6):713–718.
   Google Scholar
• Koukourakis GV, Sotiropoulou-Lontou A. Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer. Clin Transl Oncol. 2011 Oct;13(10):710–714.
   Google Scholar
• Escudier B, Cosaert J, Jethwa S. Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. Biologics: Targets & Therapy. 2008 Sep;2(3):517–530.
   Google Scholar
• Della Pepa C, Banerjee S. Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer. Oncotargets Ther. 2014;7:1025–1032.
   Google Scholar
• Dowell JE, Dunphy FR, Taub RN, et al. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer. 2012 Sep;77(3):567–571.
   Google Scholar
• Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Apr 02;387(10026):1405–1414.
   Google Scholar
• Dudek AZ, Pang H, Kratzke RA, et al. Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. J Thoracic Oncology: off Pub Int Assoc Study Lung Cancer. 2012 Apr;7(4):755–759.
   Google Scholar
• Papa S, Popat S, Shah R, et al. Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. J Thoracic Oncology: off Pub Int Assoc Study Lung Cancer. 2013 Jun;8(6):783–787.
   Google Scholar
• Belani CP, Yamamoto N, Bondarenko IM, et al. Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. Bmc Cancer. 2014 Apr 25;14.
   Google Scholar
• Buikhuisen WA, Scharpfenecker M, Griffioen AW, et al. II Study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma: a single-center trial combining clinical and translational outcomes. J Thorac Oncol. 2016 May;11(5):758–768.
   Google Scholar
• Garland LL, Chansky K, Wozniak AJ, et al. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thoracic Oncology: off Pub Int Assoc Study Lung Cancer. 2011 Nov;6(11):1938–1945.
   Google Scholar
• Nowak AK, Millward MJ, Creaney J, et al. A Phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol. 2012 Sep;7(9):1449–1456.
   Google Scholar
• Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007 Jun;1(1):19–25.
   Google Scholar
• Neuzil J, Swettenham E, Gellert N. Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. Biochem Biophys Res Commun. 2004 Jan 30;314(1):186–191.
   Google Scholar
• Kelly WK, O’Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005 Jun 10;23(17):3923–3931.
   Google Scholar
• Krug LM, Kindler HL, Calvert H, et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015 Apr;16(4):447–456.
   Google Scholar
• Ramalingam SS, Belani CP, Ruel C, et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thoracic Oncology: off Pub Int Assoc Study Lung Cancer. 2009 Jan;4(1):97–101.
   Google Scholar
• Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014 Sep;14(9):598–610.
   Google Scholar
• Poulikakos PI, Xiao GH, Gallagher R, et al. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene. 2006 Sep 28;25(44):5960–5968.
   Google Scholar
• Soria JC, Gan HK, Blagden SP, et al. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Ann Oncology: Official Journal Eur Soc Med Oncol. 2016 Dec;27(12):2268–2274.
   Google Scholar
• Fennell DA, McDowell C, Busacca S, et al. Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. J Thorac Oncol. 2012 Sep;7(9):1466–1470.
   Google Scholar
• Nowak AK, Brown C, Millward MJ, et al. A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer. 2013 Sep;81(3):422–427.
   Google Scholar
• Kalra N, Zhang J, Yu Y, et al. Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell. Int J Cancer. 2012 Nov 01;131(9):2143–2152.
   Google Scholar
• Porta C, Paglino C, Mutti L. Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma. Biologics: Targets & Therapy. 2008 Dec;2(4):601–609.
   Google Scholar
• Costanzi J, Sidransky D, Navon A, et al. Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase. Cancer Invest. 2005;23(7):643–650.
   Google Scholar
• Chu W-M. Tumor necrosis factor. Cancer Lett. 2013 Oct 22;328(2):222–225.
   Google Scholar
• Stevenson JP, Kindler HL, Papasavvas E, et al. Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology. 2013;2(8):e26218.
   Google Scholar
• Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212–20217.
   Google Scholar
• Kalra N, Ashai A, Xi L, et al. Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors. Oncol Rep. 2012 Jun;27(6):1794–1800.
   Google Scholar
• Enomoto Y, Kasai T, Takeda M, et al. Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma. J Clin Pathol. 2012 Jun;65(6):522–527.
   Google Scholar
• Graziani I, Eliasz S, De Marco MA, et al. Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway. Cancer Res. 2008 Dec 01;68(23):9678–9685.
   Google Scholar
• Goudarzi H, Iizasa H, Furuhashi M, et al. Enhancement of in vitro cell motility and invasiveness of human malignant pleural mesothelioma cells through the HIF-1alpha-MUC1 pathway. Cancer Lett. 2013 Oct 01;339(1):82–92.
   Google Scholar
• Ivanov S, Liao SY, Ivanova A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol. 2001 Mar;158(3):905–919.
   Google Scholar
• Francis RJ, Segard T, Morandeau L, et al. Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT. Lung Cancer. 2015 Oct;90(1):55–60.
   Google Scholar
• Manente AG, Valenti D, Pinton G, et al. Estrogen receptor beta activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo. Oncogenesis. 2013 Sep 23; 2:e72.
   Google Scholar